Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis

Conditions

Mental Health & Behavioral Research

Phase Pilot

What is the purpose of this trial?

The primary objective of this study is to determine whether aspirin is effective in alleviating symptoms of the clinical high risk (CHR) syndrome for psychosis. The investigators further aim to determine whether it may delay or prevent the onset of psychosis in those currently experiencing CHR symptoms. As secondary measures the investigators aim to collect laboratory studies of inflammation markers and genetic samples to determine whether certain genetic profiles correlate with risk for psychosis, or response to aspirin treatment.

  • Trial with
    Yale University School of Medicine
  • Start Date
    03/27/2014
  • End Date
    02/27/2016

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Barbara Walsh

  • Last Updated
    02/22/2018
  • Study HIC
    #1401013288